Expanded monitoring, new treatments and the power of music therapy
World Sickle Cell Day is celebrated on June 19 every year.
The observation aims to raise awareness of sickle cell disease, as well as the challenges faced by patients.
In conjunction with World Sickle Cell Day, Healio presents the following updates on sickle cell treatment and research.
- The CDC established the Sickle Cell Disease Data Collection Program to compile data on complications, treatments, health outcomes, and healthcare access for people with sickle cell disease in 11 states. Healio spoke with Mary Hulihan, DrPH, health scientist in the Epidemiology and Surveillance Branch of the Division of Blood Disorders at the CDC’s National Center for Birth Defects and Developmental Disabilities, on the potential value of the data collected through this program. Read more.
- Exposure to systemic corticosteroids appears to increase the risk of hospitalization for vaso-occlusive episodes in patients with sickle cell disease. Read more.
- An experimental gene-modified CRISPR/Cas9 cell therapy has demonstrated significant and long-lasting efficacy in patients with transfusion-dependent beta-thalassemia and sickle cell disease. Read more.
- The prevalence of organ dysfunction appeared to be low in pediatric patients who underwent hematopoietic stem cell transplantation for sickle cell disease. Read more.
- Sickle cell disease has increased the risk of transplant-associated thrombotic microangiopathy in children who have undergone hematopoietic stem cell transplantation. Read more.
- Most adolescent and young adult males with sickle cell disease said they wanted to have children later in life, but few knew about the fertility issues associated with the condition. Read more.
- UCSF Benioff Children’s Hospital in Oakland will launch a 4-year trial to evaluate CRISPR/Cas9 gene editing as a potential cure for sickle cell disease. Read more.
- Healio spoke with Samuel Rodgers-Melnick, MT-BC, on the potential of music therapy intervention to treat pain and functional deficits caused by sickle cell disease. Read more.
- LentiGlobin gene therapy (bb1111; bluebird bio) resulted in reduced hemolysis and complete resolution of severe vaso-occlusive events in a small cohort of patients with sickle cell disease. Read more.